Literature DB >> 23142076

Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?

Johanna Hynninen1, Maija Lavonius, Sinikka Oksa, Seija Grénman, Olli Carpén, Annika Auranen.   

Abstract

OBJECTIVE: Most cases of epithelial ovarian cancer (EOC) are diagnosed in an advanced stage. When the disease has spread intra-abdominally, complete surgical tumor debulking is the single most important prognostic factor. Neoadjuvant chemotherapy (NACT) before surgery can cause fibrosis and adhesions in the peritoneal cavity and may interfere with the perioperative evaluation of tumor spread. In this prospective study, we evaluated whether perioperative visual assessment of tumor dissemination is similar in patients undergoing primary and interval surgery for EOC.
METHODS: Systematic visual evaluation of tumor spread was performed at the start of primary surgery/diagnostic laparoscopy (n=39) or interval surgery (n=16). Peritoneal cavity was divided into 22 anatomical regions. The carefully documented results of the visual assessment were compared with the histopathological analysis of 220 biopsies from primary and 92 biopsies from interval surgery.
RESULTS: In primary surgery, perioperative visual estimation of tumor spread showed 98% sensitivity, 76% specificity and 95% accuracy compared to histopathology. The corresponding figures after NACT were 86%, 76% and 84%, respectively. The difference in sensitivity and accuracy in primary and interval operations was statistically significant (p<0.001).
CONCLUSIONS: In advanced EOC, microscopically carcinomatous areas have a benign visual appearance more often after NACT than at primary surgery. NACT may interfere with the perioperative visual evaluation of tumor spread and thus lead to incomplete resection of tumor in potentially resectable areas.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23142076     DOI: 10.1016/j.ygyno.2012.11.007

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.

Authors:  Seiya Sato; Hiroaki Itamochi
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

2.  Risk factors of perioperative complications and management with enhanced recovery after primary surgery in women with epithelial ovarian carcinoma in a single center.

Authors:  Min Li; Tianjiao Zhang; Jing Zhu; Yuebo Li; Wenying Chen; Yanhu Xie; Wei Zhang; Rongzhu Chen; Wei Wei; Guihong Wang; Jiwei Qin; Weidong Zhao; Dabao Wu; Zhen Shen; Björn Nashan; Ying Zhou
Journal:  Oncol Lett       Date:  2022-03-16       Impact factor: 3.111

3.  Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.

Authors:  Zibi Marchocki; Alicia Tone; Carl Virtanen; Richard de Borja; Blaise Clarke; Theodore Brown; Taymaa May
Journal:  J Ovarian Res       Date:  2022-05-02       Impact factor: 5.506

Review 4.  Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.

Authors:  Amin P Makar; Claes G Tropé; Philippe Tummers; Hannelore Denys; Katrien Vandecasteele
Journal:  Oncologist       Date:  2016-03-23

5.  Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?

Authors:  Yuki Himoto; Paulina Cybulska; Fuki Shitano; Evis Sala; Junting Zheng; Marinela Capanu; Stephanie Nougaret; Ines Nikolovski; Hebert A Vargas; Wei Wang; Jennifer J Mueller; Dennis S Chi; Yulia Lakhman
Journal:  Gynecol Oncol       Date:  2019-09-12       Impact factor: 5.482

6.  Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer.

Authors:  Marianne J Rutten; Gabe S Sonke; Anneke M Westermann; Willemien J van Driel; Johannes W Trum; Gemma G Kenter; Marrije R Buist
Journal:  Obstet Gynecol Int       Date:  2015-05-27

7.  Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.

Authors:  Yasmin A Lyons; Henry D Reyes; Megan E McDonald; Andreea Newtson; Eric Devor; David P Bender; Michael J Goodheart; Jesus Gonzalez Bosquet
Journal:  Int J Gynecol Cancer       Date:  2020-04-26       Impact factor: 3.437

8.  Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer.

Authors:  Ioannis A Voutsadakis
Journal:  Gynecol Oncol Rep       Date:  2016-11-20

9.  Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study.

Authors:  Aditi Bhatt; Pascal Rousset; Dario Baratti; Daniele Biacchi; Nazim Benzerdjeb; Ignace H J T de Hingh; Marcello Deraco; Vadim Gushchin; Praveen Kammar; Daniel Labow; Edward Levine; Brendan Moran; Faheez Mohamed; David Morris; Sanket Mehta; Aviram Nissan; Mohammad Alyami; Mohammad Adileh; Shoma Barat; Almog Ben Yacov; Kurtis Campbell; Kathleen Cummins-Perry; Delia Cortes-Guiral; Noah Cohen; Loma Parikh; Samer Alammari; Galal Bashanfer; Anwar Alshukami; Kaushal Kundalia; Gaurav Goswami; Vincent van de Vlasakker; Michelle Sittig; Paolo Sammartino; Armando Sardi; Laurent Villeneuve; Kiran Turaga; Yutaka Yonemura; Olivier Glehen
Journal:  BMJ Open       Date:  2021-07-05       Impact factor: 2.692

10.  Histopathologic tumor spreading in primary ovarian cancer with modified posterior exenteration.

Authors:  Kazuyoshi Kato; Kyoko Nishikimi; Shinichi Tate; Takako Kiyokawa; Makio Shozu
Journal:  World J Surg Oncol       Date:  2015-07-31       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.